To assess the angiographic performance of the Magic Touch Sirolimus-Coated Balloon (SCB) at 9 months follow-up after PCI for de novo CAD.~Primary end-points:~Late lumen loss (LLL) at the SCB-treated segment within 9 months after the index procedure;~Mean net lumen diameter gain at the SCB-treated segment at 9 months angiographic follow-up.~Secondary end-points:~Procedural success defined as both SCB delivery and inflation at the target lesion site with <30% diameter stenosis (DS) in the SCB-treated segment and distal Thrombolysis In Myocardial Infarction (TIMI) 3 flow;~Peri-procedural myocardial infarction (PMI) defined according to the EXCEL trial (creatinine kinase myocardial band) or Society for Cardiovascular Angiography and Interventions definitions (troponin);~Binary restenosis rate at the SCB-treated segment at 9 months angiographic follow-up;~A Device Oriented Composite End-point (DOCE) and its singular components (cardiac death, any target-vessel myocardial infarction excluding PMI, ischemia-driven target lesion revascularization) in-hospital, within 7 days after PCI; phone follow-up at 30-day (+/- 7 days) and 12 months (+/- 1 month) and a follow-up visit at 9 months (+/- 1 month). Any definite/probable SCB-treated segment thrombosis (in-hospital, within 7 days after PCI and at 30-day, 9-month, 1-year follow-up).
Evaluate angiographic performance in long lesions of Sirolimus Eluting Balloon Magic Touch by Concept Medical